Immunotherapy News and Research

Latest Immunotherapy News and Research

Stamford Hospital to participate in US FDA Expanded Access Treatment IND program for Generex Oral-lyn

Generex Biotechnology Corporation announced today that Stamford Hospital has agreed to participate in the United States Food and Drug Administration Expanded Access Treatment Investigational New Drug Program for Generex Oral-lyn, the Company's proprietary buccal insulin spray product for the treatment of patients with diabetes.

24 Feb 2011

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii.

22 Feb 2011

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

Australian health care company Prima BioMed Ltd announced today that there has been an agreement for strategy and design of the Phase III clinical registration trial for the CVac™ immunotherapy therapeutic ovarian cancer vaccine.

19 Feb 2011

The Children's Hospital of Philadelphia establishes Jeffrey Modell Endowed Chair in Pediatric Immunology Research

The Children's Hospital of Philadelphia today announced the establishment of the Jeffrey Modell Endowed Chair in Pediatric Immunology Research.

16 Feb 2011

Advaxis added to Mentor Capital Cancer Immunotherapy Index

Mentor Capital, Inc. reports that Advaxis, Inc. has been added as the newest member of the Mentor Capital Cancer Immunotherapy Index.

16 Feb 2011

RPCI offers first FDA-approved cancer treatment vaccine

The nation's first FDA-approved cancer treatment vaccine, Provenge, is being offered for the first time in Western New York at Roswell Park Cancer Institute.

15 Feb 2011

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

Cell Medica, a leading UK cellular therapeutics company that develops, manufactures and markets cellular immunotherapy products for the treatment of infectious disease and cancer, announces today that the first patient has been treated in the CMV~ACE/ASPECT trial at University College Hospital London.

10 Feb 2011

Elan 2010 total revenue increases 5% to $1,169.7 million

Elan Corporation, plc today reported its fourth quarter and full-year 2010 financial results and provided financial guidance for 2011.

8 Feb 2011

Dermatologists advise parents of young children about atopic dermatitis, food allergies

Atopic dermatitis, one of the most common forms of eczema in this family of inflammatory skin diseases, is a chronic disease marked by red, cracked and itchy skin. Now, increasing evidence indicates atopic dermatitis is a precursor to allergic diseases rather than a consequence. Dermatologists are advising parents of infants and young children affected by this common skin condition to be aware of the potential for future food allergies.

5 Feb 2011

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.

4 Feb 2011

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon DNA vaccine for prostate cancer targeting two antigens.

2 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ToleroMune(R) cat allergy treatment significantly reduced patients' symptoms in a recently completed, large-scale phase II clinical trial. The study also confirmed the treatment's highly favourable safety profile.

1 Feb 2011

Novel personalized therapy could treat metastatic melanoma and metastatic synovial cell sarcoma

Researchers have found that a novel form of personalized therapy that genetically engineers a patient's own anti-tumor immune cells to fight tumors could treat metastatic melanoma and metastatic synovial cell sarcoma, representing a potentially new therapeutic approach against these and other cancers.

1 Feb 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, is pleased to announce that the first group of patients receiving the lowest dose of SCIB1 in the Phase I clinical trial has been evaluated by the Cohort Review Committee.

31 Jan 2011

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Dr. John Rothman, EVP of Science & Operations of Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, moderated a panel discussion titled, "Live Cancer Vaccines."

29 Jan 2011

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Agenus Inc. today announced it has entered into a research agreement with Memorial Sloan-Kettering Cancer Center (MSKCC) using Agenus' proprietary cancer vaccine technology.

24 Jan 2011

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Northwest Biotherapeutics announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax for Glioblastoma multiforme brain cancer.

24 Jan 2011

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Immune Network, a company in the business of development and commercialization of immune therapies, announced today that its newly acquired business, Immunitor, has published interim data from the ongoing Phase IIb imm01 clinical trial of V5 in tuberculosis conducted at its second site in Ukraine.

24 Jan 2011

Immunotherapy News and Research

Latest Immunotherapy News and Research

Stamford Hospital to participate in US FDA Expanded Access Treatment IND program for Generex Oral-lyn

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

The Children's Hospital of Philadelphia establishes Jeffrey Modell Endowed Chair in Pediatric Immunology Research

Advaxis added to Mentor Capital Cancer Immunotherapy Index

RPCI offers first FDA-approved cancer treatment vaccine

First patient treated in cytomegalovirus~ACE/ASPECT Phase II randomised clinical trial

Elan 2010 total revenue increases 5% to $1,169.7 million

Dermatologists advise parents of young children about atopic dermatitis, food allergies

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Inovio publishes scientific paper detailing SynCon DNA vaccine preclinical study for prostate cancer

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Circassia Phase II clinical trial confirms safety profile of ToleroMune cat allergy treatment

Novel personalized therapy could treat metastatic melanoma and metastatic synovial cell sarcoma

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Cohort Review Committee evaluates SCIB1 dose escalation, safety in Phase 1 trial

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Agenus enters research agreement with Memorial Sloan-Kettering Cancer Center

Northwest Biotherapeutics resumes enrollment in DCVax Phase II clinical trial for GBM brain cancer

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in